BlossomHill (BLSM) CMO Geoffrey Oxnard Receives 61,783-Share Award

What Happened Geoffrey Oxnard, Chief Medical Officer of BlossomHill Therapeutics (BLSM), was granted a derivative equity award of 61,783 shares on August 6, 2026. The filing reports the shares at $0.00 per share (aggregate $0) as an award/grant (transaction code A). This is a grant of stock subject to vesting, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-08-06; Filing date: 2026-08-10 (appears later than the typical 2-business-day Form 4 reporting window).
• Grant: 61,783 shares; reported price: $0.00; aggregate reported value: $0 (derivative award).
• Amount owned after transaction: Not disclosed in the Form 4 filing.
• Vesting (per footnote F1): 25% of the shares vest on August 6, 2027; the remaining shares vest in equal monthly installments over the following 36 months.
• No indication in the filing of a 10b5-1 plan, tax-withholding disposition, or immediate sale.

Context This was an equity grant that will vest over time, so it does not represent immediate share ownership or a market purchase. The award's future economic value depends on BlossomHill’s share price when portions vest; the filing does not show an immediate exercise or cashless sale. The slightly delayed filing date is worth noting for investors tracking timely insider disclosures.